BIO-INTEL RETURNS TO OUR ROOTS OF SUPPLY CHAIN MANAGEMENT IN LIFE SCIENCES

April 02, 2021

Devendra Mishra, Executive Director, BSMA (4/2/2021)

A year ago, we launched the weekly newsletter Bio-Intel to keep our community informed about the global impact of the unprecedented COVID-19 Pandemic. Best published articles relating to supply chain management which became a ubiquitous subject, from Main Street to Wall Street and C-Suite, were collated to be a resource for the professionals in the industry. Today, we stand at a major milestone where we have discovered how to transform and reimagine the supply chain of the biotech, pharmaceutical, vaccines, medical devices and diagnostics segments of Life Sciences. It is opportune for us to expand our coverage to the holistic supply chain to meet the challenges of transforming global healthcare for we live in an interdependent world.

The newsletter will report on the relevant perspectives of Companies, Universities, People, Progress, Solutions and Challenges to help professionals to remain current in areas of supply chain management. Subjects to be covered will be drug innovations, strategic events of companies, executive news, supply chain matters, technology, FDA regulations, research, and international reports. Editorials will present thought leadership from diverse sources. Best practices from other industries will be focused on as well. Advertisement supported articles will appear to offer solutions by service providers, material suppliers, management consultants and technology enablers.

Seismic shifts are taking place in the world which are about the reconfiguration of the global supply chain to maximize healthcare. Operation Warp Speed demonstrated how the timeline for development of a vaccine can be reduced from ten years to ten months. We have reported on Gavi, the Global Vaccine Alliance, which has brought together public and private sectors with the shared goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries. The collaboration of Johnson and Johnson and Merck to manufacture a vaccine has been heralded as unprecedented. A $29 Billion deal has been announced to link U.S., Mexico and Canada by rail to connect the railroad between the three countries which has unique implications for the economy of the region.

The singular goal of the publication is to be the first report you scan with your first cup of coffee every Friday so that you are on top of happenings of the week which affect what you do. It is designed to deliver the emerging value chain of the industry. We look forward to improving the publication with “Letters to the Editor”. Give us your feedback as we restore our perspective of reporting.

 

 

Related Articles

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This